৳ 3,200/unit
Pack: ৳ 96,000
৳ 3,200/unit
Pack: ৳ 96,000
At a glance
Lorlatinib is a kinase inhibitor used for ALK-positive non-small cell lung cancer (NSCLC) that has progressed on crizotinib and at least one other ALK inhibitor, or alectinib or ceritinib.
Indications
- ALK-positive metastatic non-small cell lung cancer (NSCLC) - progressed on crizotinib and at least one other ALK inhibitor, or alectinib or ceritinib
Pharmacology
Lorlatinib inhibits ALK and ROS1 kinases, disrupting ALK- and ROS1-mediated signaling and inhibiting tumor cell growth in ALK- and ROS1-overexpressing tumor cells.
Dosage
Adult Dose (Oral):
- 100 mg once daily
- With or without food
- Continue until disease progression or unacceptable toxicity
- First dose reduction: 75 mg/day; Second dose reduction: 50 mg/day
Hepatic Impairment: Mild: no dose adjustment; Moderate-severe: recommended dose not established
Side effects
Common Side Effects (>10%):
- Hypercholesterolemia (96%)
- Hypertriglyceridemia (90%)
- Edema (57%)
- Hyperglycemia (52%)
- Anemia (52%)
- Peripheral neuropathy (47%)
- Increased AST (37%), ALT (28%)
- Cognitive effects (27%)
- Dyspnea (27%)
- Fatigue (26%)
- Weight gain (24%)
- Mood effects (23%)
Use in pregnancy
Use in Pregnancy: Embryo-fetal harm may occur when administered to a pregnant woman. Females of reproductive potential should use effective non-hormonal contraception during treatment and for 6 months after the final dose.
Precautions & warnings
- Severe hepatotoxicity occurred with strong CYP3A inducers
- CNS effects (seizures, hallucinations, cognitive changes, mood) may occur
- Increased serum cholesterol and triglycerides; initiate or increase lipid-lowering agents
- PR interval prolongation and AV block reported; monitor ECG
- ILD/pneumonitis may occur
Overdose effects
Overdose treatment: general supportive measures; ECG monitoring recommended due to dose-dependent PR interval effects; no antidote.
Storage conditions
Store below 30°C, protected from moisture and light; keep out of reach of children.